CN102711474B - 喹唑啉化合物 - Google Patents
喹唑啉化合物 Download PDFInfo
- Publication number
- CN102711474B CN102711474B CN201080060451.4A CN201080060451A CN102711474B CN 102711474 B CN102711474 B CN 102711474B CN 201080060451 A CN201080060451 A CN 201080060451A CN 102711474 B CN102711474 B CN 102711474B
- Authority
- CN
- China
- Prior art keywords
- amino
- methoxy
- methyl
- quinazolinyl
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COc1cc(*CNC2O)c2cc1O Chemical compound COc1cc(*CNC2O)c2cc1O 0.000 description 2
- WDHALDHJHQMIGK-UHFFFAOYSA-N CCOC(C1)C(OC)=CC(N=CN2)=C1C2=O Chemical compound CCOC(C1)C(OC)=CC(N=CN2)=C1C2=O WDHALDHJHQMIGK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25764609P | 2009-11-03 | 2009-11-03 | |
| US61/257,646 | 2009-11-03 | ||
| PCT/US2010/054927 WO2011056740A1 (en) | 2009-11-03 | 2010-11-01 | Quinazoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102711474A CN102711474A (zh) | 2012-10-03 |
| CN102711474B true CN102711474B (zh) | 2014-09-10 |
Family
ID=43970282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080060451.4A Expired - Fee Related CN102711474B (zh) | 2009-11-03 | 2010-11-01 | 喹唑啉化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8859571B2 (enExample) |
| EP (1) | EP2501233B1 (enExample) |
| JP (1) | JP5836963B2 (enExample) |
| KR (1) | KR101736521B1 (enExample) |
| CN (1) | CN102711474B (enExample) |
| AU (1) | AU2010315361B2 (enExample) |
| BR (1) | BR112012010524A2 (enExample) |
| CA (1) | CA2779989A1 (enExample) |
| EA (1) | EA021439B1 (enExample) |
| ES (1) | ES2523465T3 (enExample) |
| IL (1) | IL219504A (enExample) |
| MX (1) | MX2012005155A (enExample) |
| WO (1) | WO2011056740A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2398797B1 (en) * | 2009-02-17 | 2013-11-06 | Boehringer Ingelheim International GmbH | Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases |
| CN103159685A (zh) * | 2013-04-11 | 2013-06-19 | 苏州立新制药有限公司 | 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法 |
| AU2014353006B2 (en) * | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| CN105849044B (zh) | 2013-12-26 | 2018-10-26 | 埃克森美孚研究工程公司 | Zsm-48晶体的合成 |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| CN114521196A (zh) | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| EP4405360A4 (en) | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
-
2010
- 2010-11-01 EA EA201290243A patent/EA021439B1/ru not_active IP Right Cessation
- 2010-11-01 KR KR1020127014231A patent/KR101736521B1/ko not_active Expired - Fee Related
- 2010-11-01 CN CN201080060451.4A patent/CN102711474B/zh not_active Expired - Fee Related
- 2010-11-01 AU AU2010315361A patent/AU2010315361B2/en not_active Ceased
- 2010-11-01 MX MX2012005155A patent/MX2012005155A/es active IP Right Grant
- 2010-11-01 US US13/505,324 patent/US8859571B2/en not_active Expired - Fee Related
- 2010-11-01 WO PCT/US2010/054927 patent/WO2011056740A1/en not_active Ceased
- 2010-11-01 EP EP10828947.1A patent/EP2501233B1/en active Active
- 2010-11-01 JP JP2012537925A patent/JP5836963B2/ja not_active Expired - Fee Related
- 2010-11-01 ES ES10828947.1T patent/ES2523465T3/es active Active
- 2010-11-01 BR BR112012010524A patent/BR112012010524A2/pt not_active IP Right Cessation
- 2010-11-01 CA CA2779989A patent/CA2779989A1/en not_active Abandoned
-
2012
- 2012-04-30 IL IL219504A patent/IL219504A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120112441A (ko) | 2012-10-11 |
| ES2523465T3 (es) | 2014-11-26 |
| IL219504A (en) | 2016-09-29 |
| AU2010315361B2 (en) | 2014-06-12 |
| BR112012010524A2 (pt) | 2017-12-12 |
| EP2501233A4 (en) | 2013-06-19 |
| EP2501233A1 (en) | 2012-09-26 |
| JP2013510155A (ja) | 2013-03-21 |
| EA201290243A1 (ru) | 2012-12-28 |
| CA2779989A1 (en) | 2011-05-12 |
| MX2012005155A (es) | 2012-08-31 |
| US8859571B2 (en) | 2014-10-14 |
| AU2010315361A1 (en) | 2012-05-24 |
| EA021439B1 (ru) | 2015-06-30 |
| US20120220588A1 (en) | 2012-08-30 |
| WO2011056740A1 (en) | 2011-05-12 |
| IL219504A0 (en) | 2012-06-28 |
| CN102711474A (zh) | 2012-10-03 |
| KR101736521B1 (ko) | 2017-05-16 |
| EP2501233B1 (en) | 2014-09-24 |
| JP5836963B2 (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114040911B (zh) | 作为nav1.8抑制剂的2,3-二氢喹唑啉化合物 | |
| ES3036467T3 (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
| AU2015222584B2 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| US9890168B2 (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| CN102711474B (zh) | 喹唑啉化合物 | |
| WO2011088027A1 (en) | Compounds and methods | |
| CN112313207B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
| WO2015060373A1 (ja) | キナゾリノンおよびイソキノリノン誘導体 | |
| KR20170054421A (ko) | 브로모도메인 억제제로서의 테트라하이드로퀴놀린 유도체 | |
| US20120157482A1 (en) | Compounds and methods | |
| WO2011088031A1 (en) | Compounds and methods | |
| CN113943251B (zh) | 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途 | |
| HK40090980A (zh) | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 | |
| HK40074494A (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
| TW202246261A (zh) | 作為抗癌劑的化合物 | |
| HK40074494B (zh) | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 | |
| KR20050110439A (ko) | 퀴나졸린 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140910 Termination date: 20181101 |